Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare alloimmune disorder of pregnancy characterized by a low fetal blood platelet count that affects babies in utero or immediately after birth. Platelets are crucial in the prevention of bleeding. The spectrum of effects can vary significantly, ranging from a low platelet count without symptoms to severe complications that can become fatal.
Pregnancies at risk of FNAIT may be eligible for the FREESIA-3 research study. In this study, doctors are evaluating an investigational medication for FNAIT. Patients who qualify will receive:
• Study-required medication and care at no cost.
• Study-related evaluations of their health as well as their baby’s health.
Click here to learn more about the FREESIA-3 study today!
